|

JNJ-79635322 Clinical Trials

6 actively recruiting trials across 4 locations

▲ +1 trial since June 2026

Pipeline

Phase 1: 2Phase 2: 2Phase 3: 2

Top Sponsors

  • Janssen Research & Development, LLC5
  • University of Heidelberg Medical Center1

Indications

  • Cancer6
  • Multiple Myeloma5
  • Previously Treated Amyloid Light-chain (AL) Amyloidosis1
  • Relapsed or Refractory Multiple Myeloma1

Other2 trials

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Phase 2

Birmingham, Alabama1 trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

O Neal Comprehensive Cancer Center at UAB

Phase 2

Little Rock, Arkansas1 trial

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

UAMS

Phase 3

Springdale, Arkansas1 trial

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Highlands Oncology Group

Phase 3

Duarte, California1 trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

City of Hope

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.